<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37626797</PMID><DateRevised><Year>2023</Year><Month>08</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2227-9059</ISSN><JournalIssue CitedMedium="Print"><Volume>11</Volume><Issue>8</Issue><PubDate><Year>2023</Year><Month>Aug</Month><Day>18</Day></PubDate></JournalIssue><Title>Biomedicines</Title><ISOAbbreviation>Biomedicines</ISOAbbreviation></Journal><ArticleTitle>Thrombosis and Hyperinflammation in COVID-19 Acute Phase Are Related to Anti-Phosphatidylserine and Anti-Phosphatidylinositol Antibody Positivity.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2301</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biomedicines11082301</ELocationID><Abstract><AbstractText>Antiphospholipid antibodies (APLA) are strongly associated with thrombosis seen in patients with antiphospholipid syndrome. In COVID-19, thrombosis has been observed as one of the main comorbidities. In patients hospitalised for COVID-19, we want to check whether APLA positivity is associated with COVID-19-related thrombosis, inflammation, severity of disease, or long COVID-19. We enrolled 92 hospitalised patients with COVID-19 between March and April 2020 who were tested for 18 different APLAs (IgG and IgM) with a single line-immunoassay test. A total of 30 healthy blood donors were used to set the cut-off for each APLA positivity. Of the 92 COVID-19 inpatients, 30 (32.61%; 95% CI [23.41-43.29]) tested positive for APLA, of whom 10 (33.3%; 95% CI [17.94-52.86]) had more than one APLA positivity. Anti-phosphatidylserine IgM positivity was described in 5.4% of inpatients (<i>n</i> = 5) and was associated with the occurrence of COVID-19-related thrombosis (<i>p</i> = 0.046). Anti-cardiolipin IgM positivity was the most prevalent among the inpatients (<i>n</i> = 12, 13.0%) and was associated with a recorded thrombosis in their clinical history (<i>p</i> = 0.044); however, its positivity was not associated with the occurrence of thrombosis during their hospitalisation for COVID-19. Anti-phosphatidylinositol IgM positivity, with a prevalence of 5.4% (<i>n</i> = 5), was associated with higher levels of interleukin (IL)-6 (<i>p</i> = 0.007) and ferritin (<i>p</i> = 0.034). Neither of these APLA positivities was a risk factor for COVID-19 severity or a predictive marker for long COVID-19. In conclusion, almost a third of COVID-19 inpatients tested positive for at least one APLA. Anti-phosphatidylserine positivity in IgM class was associated with thrombosis, and anti-phosphatidylinositol positivity in IgM class was associated with inflammation, as noticed by elevated levels of IL-6. Thus, testing for non-criteria APLA to assess the risk of clinical complications in hospitalised COVID-19 patients might be beneficial. However, they were not related to disease severity or long COVID-19.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Alijotas-Reig</LastName><ForeName>Jaume</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-9212-3619</Identifier><AffiliationInfo><Affiliation>Systemic Autoimmune Diseases Research Unit, Vall d'Hebron Institut de Recerca (VHIR), 08035 Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Systemic Autoimmune Diseases Unit, Department of Internal Medicine, Hospital Universitari Vall d'Hebron (HUVH), 08035 Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, Faculty of Medicine, Universitat Aut&#xf2;noma de Barcelona (UAB), 08035 Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anunciaci&#xf3;n-Llunell</LastName><ForeName>Ariadna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Systemic Autoimmune Diseases Research Unit, Vall d'Hebron Institut de Recerca (VHIR), 08035 Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morales-P&#xe9;rez</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Systemic Autoimmune Disease Unit, Internal Medicine Department, Althaia Healthcare University Network of Manresa, 08243 Manresa, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trap&#xe9;</LastName><ForeName>Jaume</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Systemic Autoimmune Disease Unit, Internal Medicine Department, Althaia Healthcare University Network of Manresa, 08243 Manresa, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esteve-Valverde</LastName><ForeName>Enrique</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-1403-8419</Identifier><AffiliationInfo><Affiliation>Systemic Autoimmune Diseases Unit, Department of Internal Medicine, Hospital Universitari Parc Taul&#xed;, 08208 Sabadell, Catalonia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miro-Mur</LastName><ForeName>Francesc</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0003-3936-2693</Identifier><AffiliationInfo><Affiliation>Systemic Autoimmune Diseases Research Unit, Vall d'Hebron Institut de Recerca (VHIR), 08035 Barcelona, Catalonia, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>SB-JAR-23</GrantID><Agency>Synlab Group (Barcelona, Spain)</Agency><Country/></Grant><Grant><GrantID>Gravida-JAR-23</GrantID><Agency>Catedra UAB-Gravida Medicina i Immunologia Reproductiva (Barcelona, Spain)</Agency><Country/></Grant><Grant><GrantID>SEMCC-JAR-22</GrantID><Agency>Sociedad Espa&#xf1;ola de Medicina y Cirug&#xed;a Cosm&#xe9;tica (SEMCC)</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biomedicines</MedlineTA><NlmUniqueID>101691304</NlmUniqueID><ISSNLinking>2227-9059</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">anti-phosphatidylinositol antibody</Keyword><Keyword MajorTopicYN="N">anti-phosphatidylserine antibody</Keyword><Keyword MajorTopicYN="N">antiphospholipid antibodies</Keyword><Keyword MajorTopicYN="N">disease severity</Keyword><Keyword MajorTopicYN="N">long COVID-19</Keyword><Keyword MajorTopicYN="N">thrombosis</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>8</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>8</Month><Day>26</Day><Hour>10</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>8</Month><Day>26</Day><Hour>10</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>8</Month><Day>26</Day><Hour>1</Hour><Minute>2</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>8</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37626797</ArticleId><ArticleId IdType="pmc">PMC10452204</ArticleId><ArticleId IdType="doi">10.3390/biomedicines11082301</ArticleId><ArticleId IdType="pii">biomedicines11082301</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497&#x2013;506. doi: 10.1016/S0140-6736(20)30183-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Hui D.S., Iazhar E., Madani T.A., Ntoumi F., Kock R., Dar O., Ippolito G., Mchugh T.D., Memish Z.A., Drosten C., et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health&#x2014;The latest 2019 novel coronavirus outbreak in Wuhan, China. Int. J. Infect. Dis. 2020;91:264&#x2013;266. doi: 10.1016/j.ijid.2020.01.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.01.009</ArticleId><ArticleId IdType="pmc">PMC7128332</ArticleId><ArticleId IdType="pubmed">31953166</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J., Wang B., Xiang H., Cheng Z., Xiong Y., et al. Clinical Characteristics of 138 Hospitalized Patients with 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA J. Am. Med. Assoc. 2020;323:1061&#x2013;1069. doi: 10.1001/jama.2020.1585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.1585</ArticleId><ArticleId IdType="pmc">PMC7042881</ArticleId><ArticleId IdType="pubmed">32031570</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou P., Yang X.L., Wang X.G., Hu B., Zhang L., Zhang W., Si H.R., Zhu Y., Li B., Huang C.L., et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020;579:270&#x2013;273. doi: 10.1038/s41586-020-2012-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2012-7</ArticleId><ArticleId IdType="pmc">PMC7095418</ArticleId><ArticleId IdType="pubmed">32015507</ArticleId></ArticleIdList></Reference><Reference><Citation>Bikdeli B., Madhavan M.V., Jimenez D., Chuich T., Dreyfus I., Driggin E., Nigoghossian C.D., Ageno W., Madjid M., Guo Y., et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up. J. Am. Coll. Cardiol. 2020;75:2950&#x2013;2973. doi: 10.1016/j.jacc.2020.04.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.04.031</ArticleId><ArticleId IdType="pmc">PMC7164881</ArticleId><ArticleId IdType="pubmed">32311448</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba T., Levy J.H., Levi M., Connors J.M., Thachil J. Coagulopathy of Coronavirus Disease 2019. Crit. Care Med. 2020;48:1358&#x2013;1364. doi: 10.1097/CCM.0000000000004458.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000004458</ArticleId><ArticleId IdType="pmc">PMC7255402</ArticleId><ArticleId IdType="pubmed">32467443</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J. Thromb. Haemost. 2020;18:844&#x2013;847. doi: 10.1111/jth.14768.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14768</ArticleId><ArticleId IdType="pmc">PMC7166509</ArticleId><ArticleId IdType="pubmed">32073213</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackermann M., Verleden S.E., Kuehnel M., Haverich A., Welte T., Laenger F., Vanstapel A., Werlein C., Stark H., Tzankov Y., et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in COVID-19. N. Engl. J. Med. 2020;383:120&#x2013;128. doi: 10.1056/NEJMoa2015432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2015432</ArticleId><ArticleId IdType="pmc">PMC7412750</ArticleId><ArticleId IdType="pubmed">32437596</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradley B.T., Maioli H., Johnston R., Chaudhry I., Fink S.L., Xu H., Najafian B., Deutsch G., Lacy J.M., Williams T., et al. Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State: A case series. Lancet. 2020;396:320&#x2013;332. doi: 10.1016/S0140-6736(20)31305-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31305-2</ArticleId><ArticleId IdType="pmc">PMC7365650</ArticleId><ArticleId IdType="pubmed">32682491</ArticleId></ArticleIdList></Reference><Reference><Citation>Haberecker M., Schwarz E.I., Steiger P., Frontzek K., Scholkmann F., Zeng X., H&#xf6;ller S., Moch H., Varga Z. Autopsy-Based Pulmonary and Vascular Pathology: Pulmonary Endotheliitis and Multi-Organ Involvement in COVID-19 Associated Deaths. Respiration. 2022;101:155&#x2013;165. doi: 10.1159/000518914.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000518914</ArticleId><ArticleId IdType="pmc">PMC8678227</ArticleId><ArticleId IdType="pubmed">34525475</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwamura C., Hirahara K., Kiuchi M., Ikehara S., Azuma K., Shimada T., Kuriyama S., Ohki S., Yamamoto E., Inaba Y., et al. Elevated Myl9 reflects the Myl9-containing microthrombi in SARS-CoV-2-induced lung exudative vasculitis and predicts COVID-19 severity. Proc. Natl. Acad. Sci. USA. 2022;119:e2203437119. doi: 10.1073/pnas.2203437119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2203437119</ArticleId><ArticleId IdType="pmc">PMC9388124</ArticleId><ArticleId IdType="pubmed">35895716</ArticleId></ArticleIdList></Reference><Reference><Citation>Magro C., Mulvey J.J., Berlin D., Nuovo G., Salvatore S., Harp J., Baxter-Stoltzfus A., Laurence J. Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases. Transl. Res. J. Lab. Clin. Med. 2020;220:1&#x2013;13. doi: 10.1016/j.trsl.2020.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.trsl.2020.04.007</ArticleId><ArticleId IdType="pmc">PMC7158248</ArticleId><ArticleId IdType="pubmed">32299776</ArticleId></ArticleIdList></Reference><Reference><Citation>Laurence J., Nuovo G., Racine-Brzostek S.E., Seshadri M., Elhadad S., Crowson A.N., Mulvey J.J., Harp J., Ahamed J., Magro C. Premortem Skin Biopsy Assessing Microthrombi, Interferon Type I Antiviral and Regulatory Proteins, and Complement Deposition Correlates with Coronavirus Disease 2019 Clinical Stage. Am. J. Pathol. 2022;192:1282&#x2013;1294. doi: 10.1016/j.ajpath.2022.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2022.05.006</ArticleId><ArticleId IdType="pmc">PMC9144849</ArticleId><ArticleId IdType="pubmed">35640675</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahern D.J., Ai Z., Ainsworth M., Allan C., Allcock A., Angus B., Ansari M.A., Arancibia-C&#xe1;rcamo C.V., Aschenbrenner D., Attar M., et al. A blood atlas of COVID-19 defines hallmarks of disease severity and specificity. Cell. 2022;185:916&#x2013;938.e58. doi: 10.1016/j.cell.2022.01.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.012</ArticleId><ArticleId IdType="pmc">PMC8776501</ArticleId><ArticleId IdType="pubmed">35216673</ArticleId></ArticleIdList></Reference><Reference><Citation>Kousathanas A., Pairo-Castineira E., Rawlik K., Stuckey A., Odhams C.A., Walker S., Russell C.D., Malinauskas T., Wu Y., Millar J., et al. Whole-genome sequencing reveals host factors underlying critical COVID-19. Nature. 2022;607:97&#x2013;103. doi: 10.1038/s41586-022-04576-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04576-6</ArticleId><ArticleId IdType="pmc">PMC9259496</ArticleId><ArticleId IdType="pubmed">35255492</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelmann B., Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat. Rev. Immunol. 2013;13:34&#x2013;45. doi: 10.1038/nri3345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3345</ArticleId><ArticleId IdType="pubmed">23222502</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfeiler S., Massberg S., Engelmann B. Biological basis and pathological relevance of microvascular thrombosis. Thromb. Res. 2014;133((Suppl. S1)):S35&#x2013;S37. doi: 10.1016/j.thromres.2014.03.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2014.03.016</ArticleId><ArticleId IdType="pubmed">24759139</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba T., Helms J., Levi M., Levy J.H. Thromboinflammation in acute injury: Infections, heatstroke, and trauma. J. Thromb. Haemost. JTH. 2023 doi: 10.1016/j.jtha.2023.07.020. in press .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtha.2023.07.020</ArticleId><ArticleId IdType="pubmed">37541590</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinod K., Deppermann C. Immunothrombosis and thromboinflammation in host defense and disease. Platelets. 2021;32:314&#x2013;324. doi: 10.1080/09537104.2020.1817360.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09537104.2020.1817360</ArticleId><ArticleId IdType="pubmed">32896192</ArticleId></ArticleIdList></Reference><Reference><Citation>Petito E., Falcinelli E., Paliani U., Cesari E., Vaudo G., Sebastiano M., Cerotto V., Guglielmini G., Gori F., Malvestiti M., et al. Association of Neutrophil Activation, More Than Platelet Activation, With Thrombotic Complications in Coronavirus Disease 2019. J. Infect. Dis. 2021;223:933&#x2013;944. doi: 10.1093/infdis/jiaa756.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa756</ArticleId><ArticleId IdType="pmc">PMC7798977</ArticleId><ArticleId IdType="pubmed">33280009</ArticleId></ArticleIdList></Reference><Reference><Citation>Burzynski L.C., Humphry M., Pyrillou K., Wiggins K.A., Chan J.N.E., Figg N., Kitt L.L., Summers C., Tatham K.C., Martin P.B., et al. The Coagulation and Immune Systems Are Directly Linked through the Activation of Interleukin-1&#x3b1; by Thrombin. Immunity. 2019;50:1033&#x2013;1042.e6. doi: 10.1016/j.immuni.2019.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2019.03.003</ArticleId><ArticleId IdType="pmc">PMC6476404</ArticleId><ArticleId IdType="pubmed">30926232</ArticleId></ArticleIdList></Reference><Reference><Citation>Meroni P.L., Borghi M.O., Raschi E., Tedesco F. Pathogenesis of antiphospholipid syndrome: Understanding the antibodies. Nat. Rev. Rheumatol. 2011;7:330&#x2013;339. doi: 10.1038/nrrheum.2011.52.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2011.52</ArticleId><ArticleId IdType="pubmed">21556027</ArticleId></ArticleIdList></Reference><Reference><Citation>Butt A., Erkan D., Lee A.I. COVID-19 and antiphospholipid antibodies. Best. Pract. Res. Clin. Haematol. 2022;35:101402. doi: 10.1016/j.beha.2022.101402.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.beha.2022.101402</ArticleId><ArticleId IdType="pmc">PMC9568270</ArticleId><ArticleId IdType="pubmed">36494152</ArticleId></ArticleIdList></Reference><Reference><Citation>Knight J.S., Kanthi Y. Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome. Semin. Immunopathol. 2022;44:347&#x2013;362. doi: 10.1007/s00281-022-00916-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-022-00916-w</ArticleId><ArticleId IdType="pmc">PMC8816310</ArticleId><ArticleId IdType="pubmed">35122116</ArticleId></ArticleIdList></Reference><Reference><Citation>Schreiber K., Sciascia S., De Groot P.G., Devreese K., Jacobsen S., Ruiz-Irastroza G., Salmon J.E., Shoenfeld Y., Shovman O., Hunt B.J., et al. Antiphospholipid syndrome. Nat. Rev. Dis. Primer. 2018;4:17104. doi: 10.1038/nrdp.2017.103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrdp.2017.103</ArticleId><ArticleId IdType="pubmed">29321641</ArticleId></ArticleIdList></Reference><Reference><Citation>Shoenfeld Y., Blank M., Cervera R., Font J., Raschi E., Meroni P. Infectious origin of the antiphospholipid syndrome. Ann. Rheum. Dis. 2006;65:2&#x2013;6. doi: 10.1136/ard.2005.045443.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2005.045443</ArticleId><ArticleId IdType="pmc">PMC1797971</ArticleId><ArticleId IdType="pubmed">16344491</ArticleId></ArticleIdList></Reference><Reference><Citation>Blank M., Krause I., Fridkin M., Keller N., Kopolovic J., Goldberg I., Tobar A., Shoenfeld Y. Bacterial induction of autoantibodies to &#x3b2;2-glycoprotein-I accounts for the infectious etiology of antiphospholipid syndrome. J. Clin. Investig. 2002;109:797&#x2013;804. doi: 10.1172/JCI0212337.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI0212337</ArticleId><ArticleId IdType="pmc">PMC150905</ArticleId><ArticleId IdType="pubmed">11901188</ArticleId></ArticleIdList></Reference><Reference><Citation>Asherson R.A., Cervera R. Antiphospholipid antibodies and infections. Ann. Rheum. Dis. 2003;62:388&#x2013;393. doi: 10.1136/ard.62.5.388.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.62.5.388</ArticleId><ArticleId IdType="pmc">PMC1754545</ArticleId><ArticleId IdType="pubmed">12695147</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Xiao M., Zhang S.S., Xia P., Cao W., Jiang W., Chen H., Ding X., Zhao H., Zhang H., et al. Coagulopathy and Antiphospholipid Antibodies in Patients with COVID-19. N. Engl. J. Med. 2020;382:e38. doi: 10.1056/NEJMc2007575.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2007575</ArticleId><ArticleId IdType="pmc">PMC7161262</ArticleId><ArticleId IdType="pubmed">32268022</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuo Y., Estes S.K., Ali R.A., Gandhi A.A., Yalavarthi S., Shi H., Sule G., Gockman K., Madison J.A., Zuo M., et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci. Transl. Med. 2020;12:3876. doi: 10.1126/scitranslmed.abd3876.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abd3876</ArticleId><ArticleId IdType="pmc">PMC7724273</ArticleId><ArticleId IdType="pubmed">33139519</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollerbach A., M&#xfc;ller-Calleja N., Pedrosa D., Canisius A., Sprinzl M.F., Falter T., Rossmann H., Bodenstein M., Werner C., Sagoschen I., et al. Pathogenic lipid-binding antiphospholipid antibodies are associated with severity of COVID-19. J. Thromb. Haemost. 2021;19:2335&#x2013;2347. doi: 10.1111/jth.15455.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15455</ArticleId><ArticleId IdType="pmc">PMC8420426</ArticleId><ArticleId IdType="pubmed">34242469</ArticleId></ArticleIdList></Reference><Reference><Citation>Devreese K.M.J.J., Linskens E.A., Benoit D., Peperstraete H. Antiphospholipid antibodies in patients with COVID-19: A relevant observation? J. Thromb. Haemost. JTH. 2020;18:2191&#x2013;2201. doi: 10.1111/jth.14994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14994</ArticleId><ArticleId IdType="pmc">PMC7361253</ArticleId><ArticleId IdType="pubmed">32619328</ArticleId></ArticleIdList></Reference><Reference><Citation>Gatto M., Perricone C., Tonello M., Bistoni O., Cattelan A.M., Bursi R., Cafaro G., De Robertis E., Mencacci A., Bozza S., et al. Frequency and clinical correlates of antiphospholipid antibodies arising in patients with SARS-CoV-2 infection: Findings from a multicentre study on 122 cases. Clin. Exp. Rheumatol. 2020;38:754&#x2013;759.</Citation><ArticleIdList><ArticleId IdType="pubmed">32723434</ArticleId></ArticleIdList></Reference><Reference><Citation>Amezcua-Guerra L.M., Rojas-Velasco G., Brianza-Padilla M., V&#xe1;zquez-Rangel A., M&#xe1;rquez-Velasco R., Baranda-Tovar F., Springall R., Gonzalez-Pacheco H., Ju&#xe1;rez-Vicu&#xf1;a Y., Tavera-Alonso C., et al. Presence of antiphospholipid antibodies in COVID-19: A case series study. Ann. Rheum. Dis. 2021;80:e73. doi: 10.1136/annrheumdis-2020-218100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2020-218100</ArticleId><ArticleId IdType="pubmed">32753426</ArticleId></ArticleIdList></Reference><Reference><Citation>Espinosa G., Zamora-Mart&#xed;nez C., P&#xe9;rez-Isidro A., Neto D., Bravo-Gallego L.Y., Prieto-Gonz&#xe1;lez S., Vi&#xf1;as O., Moreno-Casta&#xf1;o A.B., Ruiz-Ortiz E., Cervera R. Persistent Antiphospholipid Antibodies Are Not Associated with Worse Clinical Outcomes in a Prospective Cohort of Hospitalised Patients With SARS-CoV-2 Infection. Front. Immunol. 2022;13:1979. doi: 10.3389/fimmu.2022.911979.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.911979</ArticleId><ArticleId IdType="pmc">PMC9257245</ArticleId><ArticleId IdType="pubmed">35812410</ArticleId></ArticleIdList></Reference><Reference><Citation>Foret T., Dufrost V., du Mont L.S., Costa P., Lefevre B., Lacolley P., Regnault V., Zuily S., Wahl D. Systematic Review of Antiphospholipid Antibodies in COVID-19 Patients: Culprits or Bystanders? Curr. Rheumatol. Rep. 2021;23:65. doi: 10.1007/s11926-021-01029-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-021-01029-3</ArticleId><ArticleId IdType="pmc">PMC8254447</ArticleId><ArticleId IdType="pubmed">34218350</ArticleId></ArticleIdList></Reference><Reference><Citation>Stelzer M., Henes J., Saur S. The Role of Antiphospholipid Antibodies in COVID-19. Curr. Rheumatol. Rep. 2021;23:72. doi: 10.1007/s11926-021-01041-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11926-021-01041-7</ArticleId><ArticleId IdType="pmc">PMC8278370</ArticleId><ArticleId IdType="pubmed">34259944</ArticleId></ArticleIdList></Reference><Reference><Citation>Taha M., Samavati L. Antiphospholipid antibodies in COVID-19: A meta-analysis and systematic review. RMD Open. 2021;7:e001580. doi: 10.1136/rmdopen-2021-001580.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/rmdopen-2021-001580</ArticleId><ArticleId IdType="pmc">PMC8103564</ArticleId><ArticleId IdType="pubmed">33958439</ArticleId></ArticleIdList></Reference><Reference><Citation>Anunciaci&#xf3;n-Llunell A., Mu&#xf1;oz C., Roggenbuck D., Frasca S., Pardos-Gea J., Esteve-Valverde E., Alijotas-Reig J., Miro-Mur F. Differences in Antiphospholipid Antibody Profile between Patients with Obstetric and Thrombotic Antiphospholipid Syndrome. Int. J. Mol. Sci. 2022;23:12819. doi: 10.3390/ijms232112819.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms232112819</ArticleId><ArticleId IdType="pmc">PMC9658219</ArticleId><ArticleId IdType="pubmed">36361608</ArticleId></ArticleIdList></Reference><Reference><Citation>Roggenbuck D., Egerer K., von Landenberg P., Hiemann R., Feist E., Burmester G.R., D&#xf6;rner T. Antiphospholipid antibody profiling&#x2014;Time for a new technical approach? Autoimmun. Rev. 2012;11:821&#x2013;826. doi: 10.1016/j.autrev.2012.02.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2012.02.016</ArticleId><ArticleId IdType="pubmed">23006529</ArticleId></ArticleIdList></Reference><Reference><Citation>Egerer K., Roggenbuck D., B&#xfc;ttner T., Lehmann B., Kohn A., von Landenberg P., Hiemann R., Feist E., Burmester G.R., D&#xf6;rner T. Single-step autoantibody profiling in antiphospholipid syndrome using a multi-line dot assay. Arthritis Res. Ther. 2011;13:R118. doi: 10.1186/ar3421.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar3421</ArticleId><ArticleId IdType="pmc">PMC3239356</ArticleId><ArticleId IdType="pubmed">21777436</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., Derksen R.H., Groot P.G.D., Koike T., Meroni P.L., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) J. Thromb. Haemost. 2006;4:295&#x2013;306. doi: 10.1111/j.1538-7836.2006.01753.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2006.01753.x</ArticleId><ArticleId IdType="pubmed">16420554</ArticleId></ArticleIdList></Reference><Reference><Citation>Ahamed J., Laurence J. Long COVID endotheliopathy: Hypothesized mechanisms and potential therapeutic approaches. J. Clin. Investig. 2022;132:e161167. doi: 10.1172/JCI161167.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI161167</ArticleId><ArticleId IdType="pmc">PMC9337829</ArticleId><ArticleId IdType="pubmed">35912863</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y., Han T., Chen J., Hou C., Hua L., He S., Guo Y., Zhang S., Wang Y., Yuan J., et al. Clinical and Autoimmune Characteristics of Severe and Critical Cases of COVID-19. Clin. Transl. Sci. 2020;13:1077&#x2013;1086. doi: 10.1111/cts.12805.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cts.12805</ArticleId><ArticleId IdType="pmc">PMC7264560</ArticleId><ArticleId IdType="pubmed">32315487</ArticleId></ArticleIdList></Reference><Reference><Citation>Serrano M., Espinosa G., Serrano A., Cervera R. Antigens and Antibodies of the Antiphospholipid Syndrome as New Allies in the Pathogenesis of COVID-19 Coagulopathy. Int. J. Mol. Sci. 2022;23:4946. doi: 10.3390/ijms23094946.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23094946</ArticleId><ArticleId IdType="pmc">PMC9102661</ArticleId><ArticleId IdType="pubmed">35563337</ArticleId></ArticleIdList></Reference><Reference><Citation>Trahtemberg U., Rottapel R., Dos Santos C.C., Slutsky A.S., Baker A., Fritzler M.J. Anticardiolipin and other antiphospholipid antibodies in critically ill COVID-19 positive and negative patients. Ann. Rheum. Dis. 2021;80:1236&#x2013;1240. doi: 10.1136/annrheumdis-2021-220206.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-220206</ArticleId><ArticleId IdType="pmc">PMC8076626</ArticleId><ArticleId IdType="pubmed">33903092</ArticleId></ArticleIdList></Reference><Reference><Citation>Meroni P.L., Borghi M.O. Antiphospholipid antibodies and COVID-19 thrombotic vasculopathy: One swallow does not make a summer. Ann. Rheum. Dis. 2021;80:1105&#x2013;1107. doi: 10.1136/annrheumdis-2021-220520.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-220520</ArticleId><ArticleId IdType="pubmed">34340980</ArticleId></ArticleIdList></Reference><Reference><Citation>Pavoni V., Gianesello L., Horton A. Antiphospholipid antibodies in critically ill COVID-19 patients with thromboembolism: Cause of disease or epiphenomenon? J. Thromb. Thrombolysis. 2021;52:542&#x2013;552. doi: 10.1007/s11239-021-02470-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-021-02470-y</ArticleId><ArticleId IdType="pmc">PMC8109223</ArticleId><ArticleId IdType="pubmed">33973157</ArticleId></ArticleIdList></Reference><Reference><Citation>Kernan K.F., Carcillo J.A. Hyperferritinemia and inflammation. Int. Immunol. 2017;29:401&#x2013;409. doi: 10.1093/intimm/dxx031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/intimm/dxx031</ArticleId><ArticleId IdType="pmc">PMC5890889</ArticleId><ArticleId IdType="pubmed">28541437</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz-Tapias P., Blank M., Anaya J.-M.M., Shoenfeld Y. Infections and vaccines in the etiology of antiphospholipid syndrome. Curr. Opin. Rheumatol. 2012;24:389&#x2013;393. doi: 10.1097/BOR.0b013e32835448b8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BOR.0b013e32835448b8</ArticleId><ArticleId IdType="pubmed">22617823</ArticleId></ArticleIdList></Reference><Reference><Citation>Gharavi A.E., Pierangeli S.S., Espinola R.G., Liu X., Colden-Stanfield M., Harris E.N. Antiphospholipid antibodies induced in mice by immunization with a cytomegalovirus-derived peptide cause thrombosis and activation of endothelial cells in vivo. Arthritis Rheum. 2002;46:545&#x2013;552. doi: 10.1002/art.10130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.10130</ArticleId><ArticleId IdType="pubmed">11840458</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdel-Wahab N., Talathi S., Lopez-Olivo M.A., Suarez-Almazor M.E. Risk of developing antiphospholipid antibodies following viral infection: A systematic review and meta-analysis. Lupus. 2018;27:572&#x2013;583. doi: 10.1177/0961203317731532.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203317731532</ArticleId><ArticleId IdType="pubmed">28945149</ArticleId></ArticleIdList></Reference><Reference><Citation>Gharavi E.E., Chaimovich H., Cucurull E., Celli C.M., Tang H., Wilson W.A., Gharavi A.E. Induction of antiphospholipid antibodies by immunization with synthetic viral and bacterial peptides. Lupus. 1999;8:449&#x2013;455. doi: 10.1177/096120339900800607.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/096120339900800607</ArticleId><ArticleId IdType="pubmed">10483013</ArticleId></ArticleIdList></Reference><Reference><Citation>Favaloro E.J., Henry B.M., Lippi G. COVID-19 and Antiphospholipid Antibodies: Time for a Reality Check? Semin. Thromb. Hemost. 2022;48:72&#x2013;92. doi: 10.1055/s-0041-1728832.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0041-1728832</ArticleId><ArticleId IdType="pubmed">34130340</ArticleId></ArticleIdList></Reference><Reference><Citation>Borghi M.O., Beltagy A., Garrafa E., Curreli D., Cecchini G., Bodio C., Grossi C., Blengino S., Tincani A., Franceschini F., et al. Anti-Phospholipid Antibodies in COVID-19 Are Different From Those Detectable in the Anti-Phospholipid Syndrome. Front. Immunol. 2020;11:584241. doi: 10.3389/fimmu.2020.584241.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.584241</ArticleId><ArticleId IdType="pmc">PMC7593765</ArticleId><ArticleId IdType="pubmed">33178218</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunt J.E., McNeil H.P., Morgan G.J., Crameri R.M., Krilis S.A. A phospholipid-beta 2-glycoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection. Lupus. 1992;1:75&#x2013;81. doi: 10.1177/096120339200100204.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/096120339200100204</ArticleId><ArticleId IdType="pubmed">1301967</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Yan X., Fan Q., Liu H., Liu X., Liu Z., Zhang Z. D-dimer levels on admission to predict in-hospital mortality in patients with COVID-19. J. Thromb. Haemost. 2020;18:1324&#x2013;1329. doi: 10.1111/jth.14859.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14859</ArticleId><ArticleId IdType="pmc">PMC7264730</ArticleId><ArticleId IdType="pubmed">32306492</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi T., Ellingson M.K., Wong P., Israelow B., Lucas C., Klein J., Silva J., Mao T., Oh J.E., Tokuyama M., et al. Sex differences in immune responses that underlie COVID-19 disease outcomes. Nature. 2020;588:315&#x2013;320. doi: 10.1038/s41586-020-2700-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2700-3</ArticleId><ArticleId IdType="pmc">PMC7725931</ArticleId><ArticleId IdType="pubmed">32846427</ArticleId></ArticleIdList></Reference><Reference><Citation>Scully E.P., Haverfield J., Ursin R.L., Tannenbaum C., Klein S.L. Considering how biological sex impacts immune responses and COVID-19 outcomes. Nat. Rev. Immunol. 2020;20:442&#x2013;447. doi: 10.1038/s41577-020-0348-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-020-0348-8</ArticleId><ArticleId IdType="pmc">PMC7288618</ArticleId><ArticleId IdType="pubmed">32528136</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi T., Iwasaki A. Sex differences in immune responses. Science. 2021;371:347&#x2013;348. doi: 10.1126/science.abe7199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abe7199</ArticleId><ArticleId IdType="pubmed">33479140</ArticleId></ArticleIdList></Reference><Reference><Citation>Favaloro E.J., Henry B.M., Lippi G. Is Lupus Anticoagulant a Significant Feature of COVID-19? A Critical Appraisal of the Literature. Semin. Thromb. Hemost. 2022;48:55&#x2013;71. doi: 10.1055/s-0041-1729856.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0041-1729856</ArticleId><ArticleId IdType="pubmed">34130341</ArticleId></ArticleIdList></Reference><Reference><Citation>Vollmer O., Tacquard C., Dieudonn&#xe9; Y., Nespola B., Sattler L., Grunebaum L., Gies V., Radosavljevic M., Kaeuffer C., Hansmann Y., et al. Follow-up of COVID-19 patients: LA is transient but other aPLs are persistent. Autoimmun. Rev. 2021;20:102822. doi: 10.1016/j.autrev.2021.102822.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2021.102822</ArticleId><ArticleId IdType="pmc">PMC8050395</ArticleId><ArticleId IdType="pubmed">33872769</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalli C., Somma V., Andreoli L., B&#xfc;ttner T., Schierack P., Mahler M., Roggenbuck D., Tincani A. Anti-phospholipid IgG antibodies detected by line immunoassay differentiate patients with anti-phospholipid syndrome and other autoimmune diseases. Autoimmun. Highlights. 2018;9:6. doi: 10.1007/s13317-018-0106-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13317-018-0106-0</ArticleId><ArticleId IdType="pmc">PMC5975024</ArticleId><ArticleId IdType="pubmed">29845583</ArticleId></ArticleIdList></Reference><Reference><Citation>Park H.S., Gu J.Y., Jung H.S., Kim H.K. Thrombotic risk of non-criteria anti-phospholipid antibodies measured by line immunoassay: Superiority of anti-phosphatidylserine and anti-phosphatidic acid antibodies. Clin. Lab. 2019;65:207&#x2013;213. doi: 10.7754/Clin.Lab.2018.171207.</Citation><ArticleIdList><ArticleId IdType="doi">10.7754/Clin.Lab.2018.171207</ArticleId><ArticleId IdType="pubmed">30868842</ArticleId></ArticleIdList></Reference><Reference><Citation>Barrett T.J., Bilaloglu S., Cornwell M., Burgess H.M., Virginio V.W., Drenkova K., Ibrahim H., Yuriditsky E., Aphinyanaphongs Y., Lifshitz M., et al. Platelets contribute to disease severity in COVID-19. J. Thromb. Haemost. 2021;19:3139&#x2013;3153. doi: 10.1111/jth.15534.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15534</ArticleId><ArticleId IdType="pmc">PMC8646651</ArticleId><ArticleId IdType="pubmed">34538015</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu A., Real F., Capron C., Rosenberg A.R., Silvin A., Dunsmore G., Zhu J., Cottoignies-Callamarte A., Mass&#xe9; J.M., Moine P., et al. Infection of lung megakaryocytes and platelets by SARS-CoV-2 anticipate fatal COVID-19. Cell Mol. Life Sci. 2022;79:365. doi: 10.1007/s00018-022-04318-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-022-04318-x</ArticleId><ArticleId IdType="pmc">PMC9201269</ArticleId><ArticleId IdType="pubmed">35708858</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Huang L., Wang Y., Li X., Ren L., Gu X., Kang L., Guo L., Liu M., Zhou X., et al. 6-month consequences of COVID-19 in patients discharged from hospital: A cohort study. Lancet Lond. Engl. 2021;397:220&#x2013;232. doi: 10.1016/S0140-6736(20)32656-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C., Haupert S.R., Zimmermann L., Shi X., Fritsche L.G., Mukherjee B. Global Prevalence of Post COVID-19 Condition or Long COVID: A Meta-Analysis and Systematic Review. J. Infect. Dis. 2022;226:1593&#x2013;1607. doi: 10.1093/infdis/jiac136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac136</ArticleId><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertin D., Kaphan E., Weber S., Babacci B., Arcani R., Faucher B., M&#xe9;nard A., Brodovitch A., Mege J.L., Bardin N. Persistent IgG anticardiolipin autoantibodies are associated with post-COVID syndrome. Int. J. Infect. Dis. 2021;113:23&#x2013;25. doi: 10.1016/j.ijid.2021.09.079.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.09.079</ArticleId><ArticleId IdType="pmc">PMC8487460</ArticleId><ArticleId IdType="pubmed">34614444</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>